Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

  • Starting March 23, updated visitor restrictions are in place at Duke Health. No visitors will be allowed into our hospitals until further notice with some limited exceptions. Outpatient restrictions have not changed. Learn More

  • Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Learn More

Phase III - Rivipansel Extension for Sickle Cell Disease - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if the medicine Rivipansel is safe and if it will help people who have sickle cell disease and are in the hospital during a pain crisis.
What is the Condition Being Studied?
Sickle Cell Disease with Vaso-Occlusive Crisis (Pain Crisis)

Who Can Participate in the Study?

- Male and female over 6 years of age
- Must have previously completed a specific study for sickle cell disease (check with study team for more information)

Age Group
Adults, Children

What is Involved?

If you join the study, you will:
- Be a part of the study for 18 months
- Be contacted monthly by the study team
- Possibly be given the medication Rivipansel intravenously (through a vein) while you are in the hospital
- Be contacted by telephone 7 days and 21 days after you have left the hospital

Study Details

Full Title
An Open-Label Extension Study to Evaluate The Safety of Rivipansel (GMI-1070) in The Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects with Sickle Cell Disease
Principal Investigator
Protocol Number
IRB: PRO00068144
NCT: NCT02433158
Phase III
Contact the Duke Recruitment Innovation Center